CDTX Cidara Therapeutics Inc.

3.13
-0.13  -4%
Previous Close 3.26
Open 3.25
52 Week Low 1.3
52 Week High 4.45
Market Cap $134,462,280
Shares 42,959,195
Float 37,355,211
Enterprise Value $90,232,280
Volume 557,248
Av. Daily Volume 207,302
Stock charts supplied by TradingView

Drug Pipeline

Drug Stage Notes
Rezafungin (CD101) ReSPECT
Prophylaxis
Phase 3
Phase 3
Phase 3 dosing of first patient announced May 20, 2020.
Rezafungin (CD101) ReSTORE
Candidemia
Phase 3
Phase 3
Phase 3 timeline for data release uncertain due to COVID-19 - noted May 13, 2020.
Rezafungin (CD101) STRIVE B
Candidemia
Phase 2
Phase 2
Phase 2 data released July 29, 2019 - noted all objectives met.
CD101 Topical - RADIANT
Vulvovaginal candidiasis (VVC)
Phase 2
Phase 2
Phase 2 data released February 21, 2017 - efficacy not evident, Development to be discontinued.

Latest News

  1. SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two oral abstracts and seven posters at IDWeek 2020, the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP), which takes place virtually Oct. 21-25, 2020.

    Cidara will detail new findings related to rezafungin, its novel once-weekly echinocandin…

    SAN DIEGO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present two oral abstracts and seven posters at IDWeek 2020, the joint annual meeting of the Infectious Diseases Society of America (IDSA), Society for Healthcare Epidemiology of America (SHEA), the HIV Medical Association (HIVMA), the Pediatric Infectious Diseases Society (PIDS) and the Society of Infectious Diseases Pharmacists (SIDP), which takes place virtually Oct. 21-25, 2020.

    Cidara will detail new findings related to rezafungin, its novel once-weekly echinocandin in Phase 3 trials for the treatment and prevention of serious fungal infections, in five poster presentations. Details are as follows:

    Title: Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Populations

    Poster ID: 1174

    Presenter: Shawn Flanagan, Cidara 

    Date: Wednesday, Oct. 21, 2020

    Session: Medical Mycology

    Title: Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin

    Poster ID: 1284

    Presenter: George R. Thompson III, University of California, Davis

    Date: Wednesday, Oct. 21, 2020

    Session: Novel Agents

    Title: Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin Poster ID: 637

    Presenter: Jose A. Vazquez, Medical College of Georgia at Augusta University

    Date: Wednesday, Oct. 21, 2020

    Session: Clinical Trials

    Title: Pharmacokinetics, Excretion, and Mass Balance of [14C]-Rezafungin Following Intravenous (IV) Administration in Healthy Adults

    Poster ID: 1286

    Presenter: Voon Ong, Cidara

    Date: Wednesday, Oct. 21, 2020

    Session: Novel Agents

    Title: A Pharmacoepidemiologic Evaluation of Echinocandin Use

    Poster ID: 43

    Presenter: Jinhee Jo, University of Houston

    Date: Wednesday, Oct. 21, 2020

    Session: Poster Session: Antimicrobial Stewardship: Outcomes Assessment (clinical and economic)

    Cidara will detail new findings from its Cloudbreak antiviral platform, specifically for the prevention and treatment of influenza, in two oral and two poster presentations on the development candidate CD377. Details are as follows:

    Title: Efficacy of CD377, a Novel Antiviral Fc-Conjugate, Against Seasonal Influenza in Lethal Mouse Infection Models

    Oral Abstract ID: 159

    Presenter: James Levin, Cidara

    Format: On demand

    Session: Novel Vaccines and Antibodies

    Title: CD377, a Novel Antiviral Fc-Conjugate, Demonstrates Potent Viral Burden Reduction against Influenza A (H1N1) in Mouse and Ferret Models

    Oral Abstract ID: 162

    Presenter: Simon Döhrmann, Cidara

    Format: On demand

    Session: Novel Vaccines and Antibodies

    Title: New Generation Antiviral Conjugate (AVC): Stable, Safe, and Single

    Poster ID: 1283

    Presenter: Voon Ong, Cidara 

    Date: Wednesday, Oct. 21, 2020

    Session: Novel Agents

    Title: Evaluation of CD377, a Novel Antiviral Fc-Conjugate (AVC), In Vitro Activity and In Vivo Efficacy in Immune-Competent and -Deficient (SCID) Lethal Mouse Models

    Poster ID: 1276

    Presenter: James Levin, Cidara

    Date: Wednesday, Oct. 21, 2020

    Session: Novel Agents

    Copies of the abstracts will be made available on the Publications section of the Cidara website. Additional details can be found on the IDWeek Interactive Program Planner.

    About Rezafungin

    Rezafungin is a novel once-weekly echinocandin being developed for both the treatment and prevention of serious fungal infections, such as candidemia and invasive candidiasis. The structure and properties of rezafungin are specifically designed to improve upon a clinically validated mechanism intended to enhance its efficacy and safety potential for patients. Cidara is currently conducting a Phase 3 clinical trial with rezafungin for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE trial) and a second Phase 3 clinical trial of once-weekly rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (ReSPECT trial).

    About Cloudbreak AVCs

    Cidara is developing a new generation of immunotherapeutic antivirals from its Cloudbreak antiviral platform that couple potent antivirals to a human antibody fragment. These long-acting, antiviral conjugates (AVCs) directly inhibit viral proliferation while simultaneously engaging the immune system. AVCs are initially being studied for the prevention and treatment of seasonal and pandemic influenza, with the potential to deliver universal protection for an entire flu season with a single dose. Cidara is also advancing preclinical and discovery AVC programs to target other life-threatening viruses, such as RSV, HIV and CoV, including COVID-19.

    About Cidara Therapeutics

    Cidara is developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

    Forward-Looking Statements

    This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "anticipates," "expect," "may," "plan" or "will". Forward-looking statements in this release include, but are not limited to, statements related to rezafungin's potential as a once-weekly treatment and its ability to prevent severe fungal infections, and statements related to our AVCs' potential to directly inhibit viral proliferation while simultaneously engaging the immune system, and the ability of our influenza AVC to deliver universal protection for an entire flu season with a single dose. Such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, such as unanticipated delays in or negative results from Cidara's clinical trials or other obstacles to the development of rezafungin. These and other risks are identified under the caption "Risk Factors" in Cidara's most recent Quarterly Report on Form 10-Q and other filings subsequently made with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise

    INVESTOR CONTACT:

    Brian Ritchie

    LifeSci Advisors

    (212) 915-2578

    MEDIA CONTACT:

    Karen O'Shea, Ph.D.

    LifeSci Communications

    (929) 469-3860

    Primary Logo

    View Full Article Hide Full Article
  2. SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in four investor conferences in September: Citi's 15th Annual BioPharma Conference, H.C. Wainwright 22nd Annual Global Investment Conference, Cantor Fitzgerald Virtual Global Healthcare Conference, and Maxim Conference: A Too Quiet Pandemic – Fungal Disease.

    Citi's 15th Annual BioPharma Conference 
    Date: Wednesday, September 9, 2020
    1x1 meetings only
       
    H.C. Wainwright 22nd Annual Global Investment Conference
    Date:

    SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in four investor conferences in September: Citi's 15th Annual BioPharma Conference, H.C. Wainwright 22nd Annual Global Investment Conference, Cantor Fitzgerald Virtual Global Healthcare Conference, and Maxim Conference: A Too Quiet Pandemic – Fungal Disease.

    Citi's 15th Annual BioPharma Conference 
    Date: Wednesday, September 9, 2020
    1x1 meetings only
       
    H.C. Wainwright 22nd Annual Global Investment Conference
    Date: Monday, September 14, 2020
    Time: 4:30 PM Eastern Time
       
    Cantor Fitzgerald Virtual Global Healthcare Conference
    Date: Wednesday, September 16, 2020
    Time: 3:20 PM Eastern Time
       
    Maxim Conference: A Too Quiet Pandemic – Fungal Disease
    Date: Thursday, September 17, 2020
    Time: 11:00 AM Eastern Time

    A live audio webcast and replay of the presentations at the H.C. Wainwright and Cantor Fitzgerald-sponsored events will be available in the Investors section on the Company's website at www.cidara.com.

    About Cidara Therapeutics

    Cidara is developing long-acting therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

    INVESTOR CONTACT:

    Brian Ritchie

    LifeSci Advisors

    (212) 915-2578

    MEDIA CONTACT:

    Karen O'Shea, Ph.D.

    LifeSci Communications

    (929) 469-3860

    Primary Logo

    View Full Article Hide Full Article
  3. SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended June 30, 2020, and provided an update on its corporate activities and product pipeline.

    "We are pleased to have dosed the first patient in our Phase 3 ReSPECT trial, which is evaluating rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT)," said Jeffrey Stein, Ph.D., President and Chief Executive Officer of Cidara. "BMT patients often follow complex, poorly tolerated drug…

    SAN DIEGO, Aug. 13, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended June 30, 2020, and provided an update on its corporate activities and product pipeline.

    "We are pleased to have dosed the first patient in our Phase 3 ReSPECT trial, which is evaluating rezafungin for the prevention of invasive fungal disease in patients undergoing allogeneic blood and marrow transplantation (BMT)," said Jeffrey Stein, Ph.D., President and Chief Executive Officer of Cidara. "BMT patients often follow complex, poorly tolerated drug regimens and rezafungin has the potential to simplify and significantly transform the treatment approach for both patients and providers. We were also pleased to have been recently added to the Russell 3000® Index, which we believe reflects investors' appreciation of Cidara's antifungal and antiviral development portfolio."

    Recent Corporate Highlights

    • Dosed first patient in ReSPECT trial: In May, Cidara dosed the first patient in its pivotal Phase 3 ReSPECT trial of rezafungin for the prevention of invasive fungal disease in patients undergoing BMT.

       
    • Added to Russell 3000 Index: In June, Cidara announced that it had been added to the Russell 3000® Index.

       
    • Presented at two investor conferences: In June, Cidara participated in the Cantor Fitzgerald Virtual Symposium, "Winning Ways to Treat Infections and COVID-19," and presented at the Raymond James Human Health Innovations Conference.

    Second Quarter 2020 Financial Results

    • Cash, cash equivalents and restricted cash totaled $64.1 million as of June 30, 2020, compared with $60.3 million as of December 31, 2019. 



    • As of June 30, 2020, Cidara had 42,019,195 shares of common stock outstanding, and 1,096,519 shares of Series X convertible preferred stock outstanding, which are convertible into 10,965,190 shares of common stock. 



    • Research and development expenses were $17.6 million and $30.6 million for the three and six months ended June 30, 2020, respectively, compared to $10.7 million and $23.4 million for the same periods in 2019. The increase in research and development expenses is primarily due to higher clinical expenses associated with the rezafungin clinical trials and increased spend on our Cloudbreak antiviral platform.



    • General and administrative expenses were $4.0 million and $8.1 million for the three and six months ended June 30, 2020, respectively, compared to $3.5 million and $7.3 million for the same periods in 2019. The increase in general and administrative expenses is primarily due to higher consulting expenses and legal expenses associated with securing intellectual property rights.



    • Net loss for the three months ended June 30, 2020 was $18.3 million, compared to a net loss of $13.5 million for the second quarter of 2019. For the six months ended June 30, 2020 and 2019, net loss was $32.8 million and $30.1 million, respectively.

    About Cidara Therapeutics

    Cidara is developing long-acting therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead antifungal candidate, rezafungin, in addition to Antiviral Fc-Conjugates (AVCs) targeting influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

    Forward-Looking Statements 

    This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "anticipates," "expect," "may," "plan" or "will". Forward-looking statements in this release include, but are not limited to, statements related to rezafungin's ability to simplify and transform the standard of care for patients facing serious fungal or viral infections, whether rezafungin will simplify and transform the treatment for patients undergoing allogeneic BMT, the ability of our rezafungin and Cloudbreak antiviral programs to address the ongoing COVID-19 pandemic and whether our inclusion in the Russell 3000 index will result in increased visibility to institutional investors. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the availability of, and participation in, financing opportunities. These and other risks are identified in our filings with the Securities and Exchange Commission ("SEC"), including without limitation our most recent Quarterly Report on Form 10-Q and other filings subsequently made by Cidara with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Cidara does not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise.

    INVESTOR CONTACT:

    Brian Ritchie

    LifeSci Advisors

    (212) 915-2578

    MEDIA CONTACT:

    Karen O'Shea, Ph.D.

    LifeSci Communications

    (929) 469-3860

    CIDARA THERAPEUTICS, INC.

    Condensed Consolidated Balance Sheets

     June 30, 2020 December 31, 2019
    (In thousands)(unaudited)  
    ASSETS   
    Cash, cash equivalents, and restricted cash$64,085  $60,268 
    Other current assets5,954  5,546 
    Non-current assets3,364  3,162 
    Total assets$73,403  $68,976 
        
    LIABILITIES AND STOCKHOLDERS' EQUITY   
    Total liabilities$32,051  $31,141 
    Stockholders' equity41,352  37,835 
    Total liabilities and stockholders' equity$73,403  $68,976 



    CIDARA THERAPEUTICS, INC.

    Condensed Consolidated Statements of Operations (unaudited)

     Three Months Ended

    June 30,
     Six Months Ended

    June 30,
    (In thousands, except share and per share data)2020 2019 2020 2019
    Revenues:       
    Collaboration revenue$3,392  $  $5,922  $ 
    Total revenues3,392    5,922   
    Operating expenses:       
    Research and development17,634  10,743  30,630  23,412 
    General and administrative3,969  3,525  8,064  7,260 
    Total operating expenses21,603  14,268  38,694  30,672 
    Loss from operations(18,211) (14,268) (32,772) (30,672)
    Other income (expense):       
    Change in fair value of contingent forward purchase obligations  681    411 
    Interest (expense) income, net(95) 40  (73) 153 
    Total other (expense) income, net(95) 721  (73) 564 
    Net loss and comprehensive loss$(18,306) $(13,547) $(32,845) $(30,108)
    Recognition of beneficial conversion feature    (2,762)  
    Net loss attributable to common shareholders$(18,306) $(13,547) $(35,607) $(30,108)
    Basic and diluted net loss per common share$(0.45) $(0.47) $(0.90) $(1.19)
            
    Shares used to compute basic and diluted net loss per common share40,965,180  28,590,651  39,410,751  25,248,314 

     

    Primary Logo

    View Full Article Hide Full Article
  4. SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020.

    Presentation Information:
    Date:Tuesday, August 11, 2020
    Time:3:30 PM ET
    Webcast:A live audio webcast and replay of the presentation will be available in the Investors section on the Company's website at www.cidara.com.

    About Cidara Therapeutics
    Cidara is developing long-acting therapeutics to improve the standard of care for patients…

    SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Tuesday, August 11, 2020.

    Presentation Information:
    Date:Tuesday, August 11, 2020
    Time:3:30 PM ET
    Webcast:A live audio webcast and replay of the presentation will be available in the Investors section on the Company's website at www.cidara.com.

    About Cidara Therapeutics

    Cidara is developing long-acting therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

    INVESTOR CONTACT:

    Brian Ritchie

    LifeSci Advisors

    (212) 915-2578

    MEDIA CONTACT:

    Karen O'Shea, Ph.D.

    LifeSci Communications

    (929) 469-3860

     

    Primary Logo

    View Full Article Hide Full Article
  5. SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced the formation of a scientific advisory board (SAB) and the appointment of four leading experts in viral and fungal infections and hematology. The SAB will work closely with the Cidara management team to help guide the direction and design of the company's development programs with an emphasis on the continued development and expansion of the company's Cloudbreak Antiviral Conjugate (AVC) program.

    "We are proud to have globally recognized key opinion leaders in virology, fungal diseases, transplant…

    SAN DIEGO, July 27, 2020 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ:CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today announced the formation of a scientific advisory board (SAB) and the appointment of four leading experts in viral and fungal infections and hematology. The SAB will work closely with the Cidara management team to help guide the direction and design of the company's development programs with an emphasis on the continued development and expansion of the company's Cloudbreak Antiviral Conjugate (AVC) program.

    "We are proud to have globally recognized key opinion leaders in virology, fungal diseases, transplant and hematology joining our newly formed SAB," said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. "The SAB members' collective expertise aligns with the advancement of our Cloudbreak antiviral conjugates into respiratory viruses such as influenza, RSV and coronavirus as well as with potential additional applications of rezafungin for the prevention of fungal infections in patients with hematologic malignancies and for Covid Associated Pulmonary Aspergillosis (CAPA)."

    Cidara Therapeutics' SAB is comprised of:

    • Frederick G. Hayden, MD, FACP, Stuart S. Richardson Professor Emeritus of Clinical Virology at University of Virginia School of Medicine; Professor Emeritus of Medicine at University of Virginia, Charlottesville, VA

       
    • Michael G. Ison, MD, MS, FIDSA, FAST, Professor, Divisions of Infectious Diseases and Organ Transplantation at Northwestern University Feinberg School of Medicine; Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service   at Northwestern University Comprehensive Transplant Center, Chicago, IL

       
    • Johan A Maertens, MD, PhD, FECCM, Professor of Internal Medicine and Hematology, Acute Leukemia and Transplantation Unit at University Hospitals Leuven; Department of Microbiology, Immunology and Transplantation at KULeuven, Leuven, Belgium

       
    • Kieren Marr, MD, MBA, Professor of Medicine and Oncology Director, Transplant and Oncology Infectious Diseases Program and Vice Chair for Innovation in Healthcare Implementation, Department of Medicine at Johns Hopkins University School of Medicine, Baltimore, MD

    About Cidara Therapeutics

    Cidara is developing long-acting therapeutics to improve the standard of care for patients facing serious fungal or viral infections. The Company's portfolio is comprised of breakthrough approaches aimed at transforming existing treatment and prevention paradigms, first with its lead antifungal candidate, rezafungin, in addition to antiviral conjugates (AVCs) targeting influenza and other viral diseases from Cidara's proprietary Cloudbreak® antiviral platform. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.

    INVESTOR CONTACT:

    Brian Ritchie

    LifeSci Advisors

    (212) 915-2578

    MEDIA CONTACT:

    Karen O'Shea, Ph.D.

    LifeSci Communications

    (929) 469-3860

    lifescicomms.com

    Primary Logo

    View Full Article Hide Full Article
View All Cidara Therapeutics Inc. News